Key clinical point: Surgery improved locoregional progression or recurrence rate in patients with de novo human epidermal growth factor receptor 2-positive (HER2+) metastatic inflammatory breast cancer (BC) who received first-line systemic therapy.

Major finding: Patients who underwent mastectomy had a median overall survival of 5.2 years from the date of surgery. Only one incidence of a locoregional progression or recurrence was reported 7.8 years after surgery, and pathological complete response was achieved by 10 patients, all of whom were alive at last follow-up.

Study details: Findings are from a retrospective study including 78 patients with de novo HER2+ metastatic inflammatory BC who received first-line systemic therapy, of which 41 patients underwent mastectomy with (n = 33) or without (n = 8) subsequent radiation therapy.

Disclosures: This study was funded by the Dana-Farber Cancer Institute IBC Research Fund and Reardon Family Fund. The authors declared serving as consultants or advisors or receiving speaker honorarium or travel support from, or holding stocks in several sources.

Source: Garrido-Castro AC et al. Clinical outcomes of de novo metastatic HER2-positive inflammatory breast cancer. NPJ Breast Cancer. 2023;9:50 (Jun 2). doi: 10.1038/s41523-023-00555-w

Key clinical point: Surgery improved locoregional progression or recurrence rate in patients with de novo human epidermal growth factor receptor 2-positive (HER2+) metastatic inflammatory breast cancer (BC) who received first-line systemic therapy.

Major finding: Patients who underwent mastectomy had a median overall survival of 5.2 years from the date of surgery. Only one incidence of a locoregional progression or recurrence was reported 7.8 years after surgery, and pathological complete response was achieved by 10 patients, all of whom were alive at last follow-up.

Study details: Findings are from a retrospective study including 78 patients with de novo HER2+ metastatic inflammatory BC who received first-line systemic therapy, of which 41 patients underwent mastectomy with (n = 33) or without (n = 8) subsequent radiation therapy.

Disclosures: This study was funded by the Dana-Farber Cancer Institute IBC Research Fund and Reardon Family Fund. The authors declared serving as consultants or advisors or receiving speaker honorarium or travel support from, or holding stocks in several sources.

Source: Garrido-Castro AC et al. Clinical outcomes of de novo metastatic HER2-positive inflammatory breast cancer. NPJ Breast Cancer. 2023;9:50 (Jun 2). doi: 10.1038/s41523-023-00555-w

Key clinical point: Surgery improved locoregional progression or recurrence rate in patients with de novo human epidermal growth factor receptor 2-positive (HER2+) metastatic inflammatory breast cancer (BC) who received first-line systemic therapy.

Major finding: Patients who underwent mastectomy had a median overall survival of 5.2 years from the date of surgery. Only one incidence of a locoregional progression or recurrence was reported 7.8 years after surgery, and pathological complete response was achieved by 10 patients, all of whom were alive at last follow-up.

Study details: Findings are from a retrospective study including 78 patients with de novo HER2+ metastatic inflammatory BC who received first-line systemic therapy, of which 41 patients underwent mastectomy with (n = 33) or without (n = 8) subsequent radiation therapy.

Disclosures: This study was funded by the Dana-Farber Cancer Institute IBC Research Fund and Reardon Family Fund. The authors declared serving as consultants or advisors or receiving speaker honorarium or travel support from, or holding stocks in several sources.

Source: Garrido-Castro AC et al. Clinical outcomes of de novo metastatic HER2-positive inflammatory breast cancer. NPJ Breast Cancer. 2023;9:50 (Jun 2). doi: 10.1038/s41523-023-00555-w

Key clinical point: A family history of estrogen receptor (ER)-positive (+) and negative (−) breast cancer (BC) as well as other cancers among first-degree relatives is associated with an increased risk for ER-subtypes of BC.

Major finding: Women with familial ER+ and ER− BC had ~2 times increased risk for ER+ (hazard ratio [HR] 1.96; 95% CI 1.84-2.09) and ER− (HR 2.67; 95% CI 2.10-3.40) BC, respectively. A family history of liver (odds ratio [OR] 1.33; 95% CI 1.05-1.67), ovarian (OR 1.28; 95% CI 1.01-1.61), and testicular (OR 1.78; 95% CI 1.01-3.14) cancers was associated with a higher risk for ER− vs ER+ BC.

Study details: Findings are from a population-based cohort study including 464,707 female participants, of which 25,273 were diagnosed with BC (including 16,286 and 3613 patients with ER+ and ER− BC, respectively).

Disclosures: This study was supported by the Swedish Research Council and other sources. The authors declared no conflicts of interest.

Source: Wang Q et al. Risk of ER-specific breast cancer by family history of ER subtypes and other cancers. J Natl Cancer Inst. 2023 (May 27). doi: 10.1093/jnci/djad104

Key clinical point: A family history of estrogen receptor (ER)-positive (+) and negative (−) breast cancer (BC) as well as other cancers among first-degree relatives is associated with an increased risk for ER-subtypes of BC.

Major finding: Women with familial ER+ and ER− BC had ~2 times increased risk for ER+ (hazard ratio [HR] 1.96; 95% CI 1.84-2.09) and ER− (HR 2.67; 95% CI 2.10-3.40) BC, respectively. A family history of liver (odds ratio [OR] 1.33; 95% CI 1.05-1.67), ovarian (OR 1.28; 95% CI 1.01-1.61), and testicular (OR 1.78; 95% CI 1.01-3.14) cancers was associated with a higher risk for ER− vs ER+ BC.

Study details: Findings are from a population-based cohort study including 464,707 female participants, of which 25,273 were diagnosed with BC (including 16,286 and 3613 patients with ER+ and ER− BC, respectively).

Disclosures: This study was supported by the Swedish Research Council and other sources. The authors declared no conflicts of interest.

Source: Wang Q et al. Risk of ER-specific breast cancer by family history of ER subtypes and other cancers. J Natl Cancer Inst. 2023 (May 27). doi: 10.1093/jnci/djad104

Key clinical point: A family history of estrogen receptor (ER)-positive (+) and negative (−) breast cancer (BC) as well as other cancers among first-degree relatives is associated with an increased risk for ER-subtypes of BC.

Major finding: Women with familial ER+ and ER− BC had ~2 times increased risk for ER+ (hazard ratio [HR] 1.96; 95% CI 1.84-2.09) and ER− (HR 2.67; 95% CI 2.10-3.40) BC, respectively. A family history of liver (odds ratio [OR] 1.33; 95% CI 1.05-1.67), ovarian (OR 1.28; 95% CI 1.01-1.61), and testicular (OR 1.78; 95% CI 1.01-3.14) cancers was associated with a higher risk for ER− vs ER+ BC.

Study details: Findings are from a population-based cohort study including 464,707 female participants, of which 25,273 were diagnosed with BC (including 16,286 and 3613 patients with ER+ and ER− BC, respectively).

Disclosures: This study was supported by the Swedish Research Council and other sources. The authors declared no conflicts of interest.

Source: Wang Q et al. Risk of ER-specific breast cancer by family history of ER subtypes and other cancers. J Natl Cancer Inst. 2023 (May 27). doi: 10.1093/jnci/djad104

Key clinical point: In patients with locally advanced breast cancer (BC), staging with ¹⁸F-labeled fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT) was more effective than conventional staging for detecting asymptomatic distant metastases.

Major finding: More than twice the number of patients undergoing PET-CT vs conventional staging were upstaged to stage IV BC (relative risk 2.4; P = .002), with combined modality treatment being received by fewer patients in the PET-CT vs conventional staging group (81% vs 89%; P = .03).

Study details: Findings are from the PET ABC study including 369 patients with invasive ductal carcinoma of the breast and TNM stage III or IIb BC who were randomly assigned to undergo ¹⁸F-labeled fluorodeoxyglucose PET-CT (whole body) or conventional staging (bone scan and CT of the chest/abdomen and pelvis).

Disclosures: This study did not report the source of funding. Some authors declared receiving honoraria from or serving as employees, consultants, or advisors for different sources.

Source: Dayes IS et al. Impact of ¹⁸F-labeled fluorodeoxyglucose positron emission tomography-computed tomography versus conventional staging in patients with locally advanced breast cancer. J Clin Oncol. 2023 (May 26). doi: 10.1200/JCO.23.00249

Key clinical point: In patients with locally advanced breast cancer (BC), staging with ¹⁸F-labeled fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT) was more effective than conventional staging for detecting asymptomatic distant metastases.

Major finding: More than twice the number of patients undergoing PET-CT vs conventional staging were upstaged to stage IV BC (relative risk 2.4; P = .002), with combined modality treatment being received by fewer patients in the PET-CT vs conventional staging group (81% vs 89%; P = .03).

Study details: Findings are from the PET ABC study including 369 patients with invasive ductal carcinoma of the breast and TNM stage III or IIb BC who were randomly assigned to undergo ¹⁸F-labeled fluorodeoxyglucose PET-CT (whole body) or conventional staging (bone scan and CT of the chest/abdomen and pelvis).

Disclosures: This study did not report the source of funding. Some authors declared receiving honoraria from or serving as employees, consultants, or advisors for different sources.

Source: Dayes IS et al. Impact of ¹⁸F-labeled fluorodeoxyglucose positron emission tomography-computed tomography versus conventional staging in patients with locally advanced breast cancer. J Clin Oncol. 2023 (May 26). doi: 10.1200/JCO.23.00249

Key clinical point: In patients with locally advanced breast cancer (BC), staging with ¹⁸F-labeled fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT) was more effective than conventional staging for detecting asymptomatic distant metastases.

Major finding: More than twice the number of patients undergoing PET-CT vs conventional staging were upstaged to stage IV BC (relative risk 2.4; P = .002), with combined modality treatment being received by fewer patients in the PET-CT vs conventional staging group (81% vs 89%; P = .03).

Study details: Findings are from the PET ABC study including 369 patients with invasive ductal carcinoma of the breast and TNM stage III or IIb BC who were randomly assigned to undergo ¹⁸F-labeled fluorodeoxyglucose PET-CT (whole body) or conventional staging (bone scan and CT of the chest/abdomen and pelvis).

Disclosures: This study did not report the source of funding. Some authors declared receiving honoraria from or serving as employees, consultants, or advisors for different sources.

Source: Dayes IS et al. Impact of ¹⁸F-labeled fluorodeoxyglucose positron emission tomography-computed tomography versus conventional staging in patients with locally advanced breast cancer. J Clin Oncol. 2023 (May 26). doi: 10.1200/JCO.23.00249

Key clinical point: Simultaneous integrated boost (SIB) radiotherapy was safe and demonstrated noninferior clinical outcomes compared with sequential photon tumor-bed boost in patients with early breast cancer (BC) who underwent breast-conserving surgery (BCS).

Major finding: SIB with 48 Gy in 15 fractions to the tumor-bed volume vs sequential photon tumor-bed boost resulted in comparable rates of ipsilateral breast tumor relapse (hazard ratio [HR] 1.04; P = .91), whereas dose-escalated SIB (53 Gy) proved disadvantageous (HR 1.76; P = .041). There was no increase in toxicity outcomes with 48 Gy SIB vs sequential photon tumor-bed boost.

Study details: Findings are from the phase 3 IMPORT HIGH study including 2617 patients with early BC who underwent BCS and were randomly assigned to receive sequential photon tumor-bed boost or SIB with 48 or 53 Gy in 15 fractions to the tumor-bed volume.

Disclosures: This study was supported by Cancer Research U.K. Some authors declared receiving grants or funding from various sources, including Cancer Research U.K.

Source: Coles CE et al. Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): A multicentre, phase 3, non-inferiority, open-label, randomised controlled trial. Lancet. 2023 (Jun 8). doi: 10.1016/S0140-6736(23)00619-0

Key clinical point: Simultaneous integrated boost (SIB) radiotherapy was safe and demonstrated noninferior clinical outcomes compared with sequential photon tumor-bed boost in patients with early breast cancer (BC) who underwent breast-conserving surgery (BCS).

Major finding: SIB with 48 Gy in 15 fractions to the tumor-bed volume vs sequential photon tumor-bed boost resulted in comparable rates of ipsilateral breast tumor relapse (hazard ratio [HR] 1.04; P = .91), whereas dose-escalated SIB (53 Gy) proved disadvantageous (HR 1.76; P = .041). There was no increase in toxicity outcomes with 48 Gy SIB vs sequential photon tumor-bed boost.

Study details: Findings are from the phase 3 IMPORT HIGH study including 2617 patients with early BC who underwent BCS and were randomly assigned to receive sequential photon tumor-bed boost or SIB with 48 or 53 Gy in 15 fractions to the tumor-bed volume.

Disclosures: This study was supported by Cancer Research U.K. Some authors declared receiving grants or funding from various sources, including Cancer Research U.K.

Source: Coles CE et al. Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): A multicentre, phase 3, non-inferiority, open-label, randomised controlled trial. Lancet. 2023 (Jun 8). doi: 10.1016/S0140-6736(23)00619-0

Key clinical point: Simultaneous integrated boost (SIB) radiotherapy was safe and demonstrated noninferior clinical outcomes compared with sequential photon tumor-bed boost in patients with early breast cancer (BC) who underwent breast-conserving surgery (BCS).

Major finding: SIB with 48 Gy in 15 fractions to the tumor-bed volume vs sequential photon tumor-bed boost resulted in comparable rates of ipsilateral breast tumor relapse (hazard ratio [HR] 1.04; P = .91), whereas dose-escalated SIB (53 Gy) proved disadvantageous (HR 1.76; P = .041). There was no increase in toxicity outcomes with 48 Gy SIB vs sequential photon tumor-bed boost.

Study details: Findings are from the phase 3 IMPORT HIGH study including 2617 patients with early BC who underwent BCS and were randomly assigned to receive sequential photon tumor-bed boost or SIB with 48 or 53 Gy in 15 fractions to the tumor-bed volume.

Disclosures: This study was supported by Cancer Research U.K. Some authors declared receiving grants or funding from various sources, including Cancer Research U.K.

Source: Coles CE et al. Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): A multicentre, phase 3, non-inferiority, open-label, randomised controlled trial. Lancet. 2023 (Jun 8). doi: 10.1016/S0140-6736(23)00619-0

Key clinical point: In patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2-positive (ERBB2+, aka HER2+) breast cancer (BC), de-escalated neoadjuvant chemotherapy with paclitaxel plus trastuzumab and pertuzumab resulted in excellent pathological complete response (pCR) rates, which were superior to those achieved with endocrine therapy plus pertuzumab and trastuzumab.

Major finding: At 12 weeks, endocrine therapy+trastuzumab+pertuzumab led to a significantly inferior pCR rate compared with paclitaxel+trastuzumab+pertuzumab (23.7% vs 56.4%; odds ratio 0.24; P < .001). Both the types of treatment were well tolerated.

Study details: Findings are from the prospective, phase 2 WSG-TP-II trial including 207 patients with HR+/ERBB2+ early BC who were randomly assigned to receive trastuzumab+pertuzumab with paclitaxel or standard endocrine therapy for 12 weeks in the neoadjuvant setting.

Disclosures: This study was supported by Roche Pharma AG. The authors declared receiving personal fees, consulting fees, payments, grants, or travel support or having other ties with Roche and other sources.

Source: Gluz O et al. Efficacy of endocrine therapy plus trastuzumab and pertuzumab vs de-escalated chemotherapy in patients with hormone receptor-positive/ERBB2-positive early breast cancer: The neoadjuvant WSG-TP-II randomized clinical trial. JAMA Oncol. 2023 (May 11). doi: 10.1001/jamaoncol.2023.0646

Key clinical point: In patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2-positive (ERBB2+, aka HER2+) breast cancer (BC), de-escalated neoadjuvant chemotherapy with paclitaxel plus trastuzumab and pertuzumab resulted in excellent pathological complete response (pCR) rates, which were superior to those achieved with endocrine therapy plus pertuzumab and trastuzumab.

Major finding: At 12 weeks, endocrine therapy+trastuzumab+pertuzumab led to a significantly inferior pCR rate compared with paclitaxel+trastuzumab+pertuzumab (23.7% vs 56.4%; odds ratio 0.24; P < .001). Both the types of treatment were well tolerated.

Study details: Findings are from the prospective, phase 2 WSG-TP-II trial including 207 patients with HR+/ERBB2+ early BC who were randomly assigned to receive trastuzumab+pertuzumab with paclitaxel or standard endocrine therapy for 12 weeks in the neoadjuvant setting.

Disclosures: This study was supported by Roche Pharma AG. The authors declared receiving personal fees, consulting fees, payments, grants, or travel support or having other ties with Roche and other sources.

Source: Gluz O et al. Efficacy of endocrine therapy plus trastuzumab and pertuzumab vs de-escalated chemotherapy in patients with hormone receptor-positive/ERBB2-positive early breast cancer: The neoadjuvant WSG-TP-II randomized clinical trial. JAMA Oncol. 2023 (May 11). doi: 10.1001/jamaoncol.2023.0646

Key clinical point: In patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2-positive (ERBB2+, aka HER2+) breast cancer (BC), de-escalated neoadjuvant chemotherapy with paclitaxel plus trastuzumab and pertuzumab resulted in excellent pathological complete response (pCR) rates, which were superior to those achieved with endocrine therapy plus pertuzumab and trastuzumab.

Major finding: At 12 weeks, endocrine therapy+trastuzumab+pertuzumab led to a significantly inferior pCR rate compared with paclitaxel+trastuzumab+pertuzumab (23.7% vs 56.4%; odds ratio 0.24; P < .001). Both the types of treatment were well tolerated.

Study details: Findings are from the prospective, phase 2 WSG-TP-II trial including 207 patients with HR+/ERBB2+ early BC who were randomly assigned to receive trastuzumab+pertuzumab with paclitaxel or standard endocrine therapy for 12 weeks in the neoadjuvant setting.

Disclosures: This study was supported by Roche Pharma AG. The authors declared receiving personal fees, consulting fees, payments, grants, or travel support or having other ties with Roche and other sources.

Source: Gluz O et al. Efficacy of endocrine therapy plus trastuzumab and pertuzumab vs de-escalated chemotherapy in patients with hormone receptor-positive/ERBB2-positive early breast cancer: The neoadjuvant WSG-TP-II randomized clinical trial. JAMA Oncol. 2023 (May 11). doi: 10.1001/jamaoncol.2023.0646

Key clinical point: Capivasertib-fulvestrant therapy demonstrated significant progression-free survival (PFS) benefit and a manageable safety profile in patients with endocrine therapy-resistant hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (BC).

Major finding: Significant PFS benefits were observed with capivasertib+fulvestrant vs placebo+fulvestrant in the overall population (hazard ratio for progression or death 0.60; P < .001) and in patients with AKT pathway-altered (PIK3CA, AKT1, or PTEN) tumors (hazard ratio 0.50; P < .001). Diarrhea and rash were the most common adverse events in the capivasertib+fulvestrant group.

Study details: Findings are from a primary analysis of the phase 3 CAPItello-291 study including 708 patients with HR+/HER2− advanced BC who had progressed on an aromatase inhibitor with or without cyclin-dependent kinase 4 and 6 inhibitor and were randomly assigned to receive fulvestrant with capivasertib or placebo.

Disclosures: This study was supported by AstraZeneca and other sources. Four authors declared being employees and stockholders in AstraZeneca. Some authors declared having ties with several sources.

Source: Turner NC et al for the CAPItello-291 Study Group. Capivasertib in hormone receptor-positive advanced breast cancer. N Engl J Med. 2023;388(22):2058-2070 (Jun 1). doi: 10.1056/NEJMoa2214131

Key clinical point: Capivasertib-fulvestrant therapy demonstrated significant progression-free survival (PFS) benefit and a manageable safety profile in patients with endocrine therapy-resistant hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (BC).

Major finding: Significant PFS benefits were observed with capivasertib+fulvestrant vs placebo+fulvestrant in the overall population (hazard ratio for progression or death 0.60; P < .001) and in patients with AKT pathway-altered (PIK3CA, AKT1, or PTEN) tumors (hazard ratio 0.50; P < .001). Diarrhea and rash were the most common adverse events in the capivasertib+fulvestrant group.

Study details: Findings are from a primary analysis of the phase 3 CAPItello-291 study including 708 patients with HR+/HER2− advanced BC who had progressed on an aromatase inhibitor with or without cyclin-dependent kinase 4 and 6 inhibitor and were randomly assigned to receive fulvestrant with capivasertib or placebo.

Disclosures: This study was supported by AstraZeneca and other sources. Four authors declared being employees and stockholders in AstraZeneca. Some authors declared having ties with several sources.

Source: Turner NC et al for the CAPItello-291 Study Group. Capivasertib in hormone receptor-positive advanced breast cancer. N Engl J Med. 2023;388(22):2058-2070 (Jun 1). doi: 10.1056/NEJMoa2214131

Key clinical point: Capivasertib-fulvestrant therapy demonstrated significant progression-free survival (PFS) benefit and a manageable safety profile in patients with endocrine therapy-resistant hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (BC).

Major finding: Significant PFS benefits were observed with capivasertib+fulvestrant vs placebo+fulvestrant in the overall population (hazard ratio for progression or death 0.60; P < .001) and in patients with AKT pathway-altered (PIK3CA, AKT1, or PTEN) tumors (hazard ratio 0.50; P < .001). Diarrhea and rash were the most common adverse events in the capivasertib+fulvestrant group.

Study details: Findings are from a primary analysis of the phase 3 CAPItello-291 study including 708 patients with HR+/HER2− advanced BC who had progressed on an aromatase inhibitor with or without cyclin-dependent kinase 4 and 6 inhibitor and were randomly assigned to receive fulvestrant with capivasertib or placebo.

Disclosures: This study was supported by AstraZeneca and other sources. Four authors declared being employees and stockholders in AstraZeneca. Some authors declared having ties with several sources.

Source: Turner NC et al for the CAPItello-291 Study Group. Capivasertib in hormone receptor-positive advanced breast cancer. N Engl J Med. 2023;388(22):2058-2070 (Jun 1). doi: 10.1056/NEJMoa2214131

Key clinical point: Presence of concurrent atopic dermatitis (AD) significantly affects the biologic-free survival in patients with inflammatory bowel disease (IBD).

Major finding: Presence of concurrent AD was associated with a significantly shorter biologic-free survival in patients with IBD (adjusted hazard ratio [aHR] 1.743; P = .032), with the association being stronger in patients with ulcerative colitis (aHR 4.769; P = .004).

Study details: Findings are from a retrospective study including 61 adult patients with IBD and concurrent AD and 122 matched control individuals with IBD alone.

Disclosures: This study was supported by the National Research Foundation of Korea grant funded by the Korea government and others. The authors declared no conflicts of interest.

Source: Kim KW, et al, and Seoul National University Inflammatory Bowel Disease Research Network (SIRN) and Inflammatory Bowel Disease Research Group of Korean Association for the Study of Intestinal Disease (KASID). Atopic dermatitis is associated with the clinical course of inflammatory bowel disease. Scand J Gastroenterol. 2023;1-7 (May 11). doi: 10.1080/00365521.2023.2209688

Key clinical point: Presence of concurrent atopic dermatitis (AD) significantly affects the biologic-free survival in patients with inflammatory bowel disease (IBD).

Major finding: Presence of concurrent AD was associated with a significantly shorter biologic-free survival in patients with IBD (adjusted hazard ratio [aHR] 1.743; P = .032), with the association being stronger in patients with ulcerative colitis (aHR 4.769; P = .004).

Study details: Findings are from a retrospective study including 61 adult patients with IBD and concurrent AD and 122 matched control individuals with IBD alone.

Disclosures: This study was supported by the National Research Foundation of Korea grant funded by the Korea government and others. The authors declared no conflicts of interest.

Source: Kim KW, et al, and Seoul National University Inflammatory Bowel Disease Research Network (SIRN) and Inflammatory Bowel Disease Research Group of Korean Association for the Study of Intestinal Disease (KASID). Atopic dermatitis is associated with the clinical course of inflammatory bowel disease. Scand J Gastroenterol. 2023;1-7 (May 11). doi: 10.1080/00365521.2023.2209688

Key clinical point: Presence of concurrent atopic dermatitis (AD) significantly affects the biologic-free survival in patients with inflammatory bowel disease (IBD).

Major finding: Presence of concurrent AD was associated with a significantly shorter biologic-free survival in patients with IBD (adjusted hazard ratio [aHR] 1.743; P = .032), with the association being stronger in patients with ulcerative colitis (aHR 4.769; P = .004).

Study details: Findings are from a retrospective study including 61 adult patients with IBD and concurrent AD and 122 matched control individuals with IBD alone.

Disclosures: This study was supported by the National Research Foundation of Korea grant funded by the Korea government and others. The authors declared no conflicts of interest.

Source: Kim KW, et al, and Seoul National University Inflammatory Bowel Disease Research Network (SIRN) and Inflammatory Bowel Disease Research Group of Korean Association for the Study of Intestinal Disease (KASID). Atopic dermatitis is associated with the clinical course of inflammatory bowel disease. Scand J Gastroenterol. 2023;1-7 (May 11). doi: 10.1080/00365521.2023.2209688

Key clinical point: Dupilumab significantly improves disease signs and symptoms in children with severe atopic dermatitis (AD), including those not achieving a clear or almost clear skin by week 16.

Major finding: At week 16, a significantly higher proportion of children in the dupilumab 200 mg+topical corticosteroid (TCS) and dupilumab 300 mg+TCS vs placebo+TCS groups achieved a ≥50% improvement in the Eczema Area and Severity Index score (both P < .0001), with patients in both treatment groups with an Investigator’s Global Assessment score of >1 also showing significant improvements (P = .0002 and P < .0001, respectively). No new safety signals were reported.

Study details: This post hoc analysis of LIBERTY AD PEDS trial included 304 children age 6-11 years with severe AD who were randomly assigned to receive dupilumab 200 mg+TCS, dupilumab 300 mg+TCS, or placebo+TCS.

Disclosures: This study was sponsored by Sanofi and Regeneron Pharmaceuticals Inc. Some authors reported ties with Sanofi-Regeneron and others. Six authors declared being employees of or holding stock or stock options in Sanofi/Regeneron.

Source: Siegfried EC et al. Dupilumab provides clinically meaningful responses in children aged 6–11 years with severe atopic dermatitis: Post hoc analysis results from a phase III trial. Am J Clin Dermatol. 2023 (Jun 10). doi: 10.1007/s40257-023-00791-7

Key clinical point: Dupilumab significantly improves disease signs and symptoms in children with severe atopic dermatitis (AD), including those not achieving a clear or almost clear skin by week 16.

Major finding: At week 16, a significantly higher proportion of children in the dupilumab 200 mg+topical corticosteroid (TCS) and dupilumab 300 mg+TCS vs placebo+TCS groups achieved a ≥50% improvement in the Eczema Area and Severity Index score (both P < .0001), with patients in both treatment groups with an Investigator’s Global Assessment score of >1 also showing significant improvements (P = .0002 and P < .0001, respectively). No new safety signals were reported.

Study details: This post hoc analysis of LIBERTY AD PEDS trial included 304 children age 6-11 years with severe AD who were randomly assigned to receive dupilumab 200 mg+TCS, dupilumab 300 mg+TCS, or placebo+TCS.

Disclosures: This study was sponsored by Sanofi and Regeneron Pharmaceuticals Inc. Some authors reported ties with Sanofi-Regeneron and others. Six authors declared being employees of or holding stock or stock options in Sanofi/Regeneron.

Source: Siegfried EC et al. Dupilumab provides clinically meaningful responses in children aged 6–11 years with severe atopic dermatitis: Post hoc analysis results from a phase III trial. Am J Clin Dermatol. 2023 (Jun 10). doi: 10.1007/s40257-023-00791-7

Key clinical point: Dupilumab significantly improves disease signs and symptoms in children with severe atopic dermatitis (AD), including those not achieving a clear or almost clear skin by week 16.

Major finding: At week 16, a significantly higher proportion of children in the dupilumab 200 mg+topical corticosteroid (TCS) and dupilumab 300 mg+TCS vs placebo+TCS groups achieved a ≥50% improvement in the Eczema Area and Severity Index score (both P < .0001), with patients in both treatment groups with an Investigator’s Global Assessment score of >1 also showing significant improvements (P = .0002 and P < .0001, respectively). No new safety signals were reported.

Study details: This post hoc analysis of LIBERTY AD PEDS trial included 304 children age 6-11 years with severe AD who were randomly assigned to receive dupilumab 200 mg+TCS, dupilumab 300 mg+TCS, or placebo+TCS.

Disclosures: This study was sponsored by Sanofi and Regeneron Pharmaceuticals Inc. Some authors reported ties with Sanofi-Regeneron and others. Six authors declared being employees of or holding stock or stock options in Sanofi/Regeneron.

Source: Siegfried EC et al. Dupilumab provides clinically meaningful responses in children aged 6–11 years with severe atopic dermatitis: Post hoc analysis results from a phase III trial. Am J Clin Dermatol. 2023 (Jun 10). doi: 10.1007/s40257-023-00791-7

Key clinical point: Abrocitinib and upadacitinib demonstrated acceptable safety profiles and provided greater improvements in disease signs and symptoms compared with dupilumab as early as week 2 in patients with moderate-to-severe atopic dermatitis (AD).

Major finding: A significantly higher proportion of patients in the abrocitinib/upadacitinib vs dupilumab group achieved a ≥75% improvement in Eczema Area and Severity Index scores and ≥4-point improvement in Peak Pruritus Numerical Rating Scale scores at 2 weeks (relative risk [RR] 1.92 and RR 1.87, respectively; both P < .001) and the end of therapy (RR 1.12; P = .002 and RR 1.20; P < .001, respectively). Although the severe adverse event rate was higher in the abrocitinib/upadacitinib vs dupilumab group (P = .043), the treatment-emergent adverse event rate leading to treatment discontinuation was similar.

Study details: This meta-analysis of three randomized controlled trials included 2256 patients with moderate-to-severe AD who received abrocitinib, upadacitinib, or dupilumab.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Gao Q et al. Efficacy and safety of abrocitinib and upadacitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: A systematic review and meta-analysis. Heliyon. 2023;9:E16704 (Jun 2). doi: 10.1016/j.heliyon.2023.e16704/p>

Key clinical point: Abrocitinib and upadacitinib demonstrated acceptable safety profiles and provided greater improvements in disease signs and symptoms compared with dupilumab as early as week 2 in patients with moderate-to-severe atopic dermatitis (AD).

Major finding: A significantly higher proportion of patients in the abrocitinib/upadacitinib vs dupilumab group achieved a ≥75% improvement in Eczema Area and Severity Index scores and ≥4-point improvement in Peak Pruritus Numerical Rating Scale scores at 2 weeks (relative risk [RR] 1.92 and RR 1.87, respectively; both P < .001) and the end of therapy (RR 1.12; P = .002 and RR 1.20; P < .001, respectively). Although the severe adverse event rate was higher in the abrocitinib/upadacitinib vs dupilumab group (P = .043), the treatment-emergent adverse event rate leading to treatment discontinuation was similar.

Study details: This meta-analysis of three randomized controlled trials included 2256 patients with moderate-to-severe AD who received abrocitinib, upadacitinib, or dupilumab.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Gao Q et al. Efficacy and safety of abrocitinib and upadacitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: A systematic review and meta-analysis. Heliyon. 2023;9:E16704 (Jun 2). doi: 10.1016/j.heliyon.2023.e16704/p>

Key clinical point: Abrocitinib and upadacitinib demonstrated acceptable safety profiles and provided greater improvements in disease signs and symptoms compared with dupilumab as early as week 2 in patients with moderate-to-severe atopic dermatitis (AD).

Major finding: A significantly higher proportion of patients in the abrocitinib/upadacitinib vs dupilumab group achieved a ≥75% improvement in Eczema Area and Severity Index scores and ≥4-point improvement in Peak Pruritus Numerical Rating Scale scores at 2 weeks (relative risk [RR] 1.92 and RR 1.87, respectively; both P < .001) and the end of therapy (RR 1.12; P = .002 and RR 1.20; P < .001, respectively). Although the severe adverse event rate was higher in the abrocitinib/upadacitinib vs dupilumab group (P = .043), the treatment-emergent adverse event rate leading to treatment discontinuation was similar.

Study details: This meta-analysis of three randomized controlled trials included 2256 patients with moderate-to-severe AD who received abrocitinib, upadacitinib, or dupilumab.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Gao Q et al. Efficacy and safety of abrocitinib and upadacitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: A systematic review and meta-analysis. Heliyon. 2023;9:E16704 (Jun 2). doi: 10.1016/j.heliyon.2023.e16704/p>

Key clinical point: Daily use of an emollient with a prebiotic lysate in the first year of life was safe but did not decrease the risk of developing atopic dermatitis (AD) in high-risk infants.

Major finding: At 2 years, the cumulative incidence of AD among infants receiving general skin care+emollient containing a prebiotic Vitreoscilla filiformis lysate (at least once daily until 1 year of age; intervention group) and general skin care (control group) was comparable (28% and 24%, respectively; adjusted relative risk 1.17; 95% CI 0.46-2.98). No emollient-related adverse events were reported.

Study details: Findings are from the randomized prospective EARLYEmollient study including 50 term-born infants aged 1-21 days with a high risk for AD who were randomly assigned to the intervention (n = 25) or control (n = 25) group.

Disclosures: This study was supported by La Roche-Posay Laboratoire Pharmaceutique, France. Some authors declared serving as lecturers or consultants, receiving institutional grants, or participating in advisory board meetings for various sources.

Source: Harder I et al. Effects of early emollient use in children at high risk of atopic dermatitis: A German pilot study. Acta Derm Venereol. 2023;103:adv5671 (May 29). doi: 10.2340/actadv.v103.5671

Key clinical point: Daily use of an emollient with a prebiotic lysate in the first year of life was safe but did not decrease the risk of developing atopic dermatitis (AD) in high-risk infants.

Major finding: At 2 years, the cumulative incidence of AD among infants receiving general skin care+emollient containing a prebiotic Vitreoscilla filiformis lysate (at least once daily until 1 year of age; intervention group) and general skin care (control group) was comparable (28% and 24%, respectively; adjusted relative risk 1.17; 95% CI 0.46-2.98). No emollient-related adverse events were reported.

Study details: Findings are from the randomized prospective EARLYEmollient study including 50 term-born infants aged 1-21 days with a high risk for AD who were randomly assigned to the intervention (n = 25) or control (n = 25) group.

Disclosures: This study was supported by La Roche-Posay Laboratoire Pharmaceutique, France. Some authors declared serving as lecturers or consultants, receiving institutional grants, or participating in advisory board meetings for various sources.

Source: Harder I et al. Effects of early emollient use in children at high risk of atopic dermatitis: A German pilot study. Acta Derm Venereol. 2023;103:adv5671 (May 29). doi: 10.2340/actadv.v103.5671

Key clinical point: Daily use of an emollient with a prebiotic lysate in the first year of life was safe but did not decrease the risk of developing atopic dermatitis (AD) in high-risk infants.

Major finding: At 2 years, the cumulative incidence of AD among infants receiving general skin care+emollient containing a prebiotic Vitreoscilla filiformis lysate (at least once daily until 1 year of age; intervention group) and general skin care (control group) was comparable (28% and 24%, respectively; adjusted relative risk 1.17; 95% CI 0.46-2.98). No emollient-related adverse events were reported.

Study details: Findings are from the randomized prospective EARLYEmollient study including 50 term-born infants aged 1-21 days with a high risk for AD who were randomly assigned to the intervention (n = 25) or control (n = 25) group.

Disclosures: This study was supported by La Roche-Posay Laboratoire Pharmaceutique, France. Some authors declared serving as lecturers or consultants, receiving institutional grants, or participating in advisory board meetings for various sources.

Source: Harder I et al. Effects of early emollient use in children at high risk of atopic dermatitis: A German pilot study. Acta Derm Venereol. 2023;103:adv5671 (May 29). doi: 10.2340/actadv.v103.5671